keyword
MENU ▼
Read by QxMD icon Read
search

Il28b

keyword
https://www.readbyqxmd.com/read/28224025/lack-of-association-between-interleukin-28b-gene-polymorphisms-rs8099917g-t-rs12979860-c-t-and-susceptibility-to-chronic-hepatitis-c-virus-infection-tehran-iran
#1
Maryam Karkhane, Seyed Reza Mohebbi, Pedram Azimzadeh, Mahsa Saeedi Niasar, Mohamad Reza Sarbazi, Afsaneh Sharifian, Afshin Mohammad Alizadeh
AIM: Chronic Hepatitis C infection is a critical health problem worldwide, which caused by hepatitis C virus (HCV). Interleukin 28B (IL28B) is a determinant factor in disease progression and also susceptibility to chronic HCV infection. BACKGROUND: The most significant aim of this study is to analyze the association between IL28B gene polymorphisms with susceptibility to chronic HCV infection in Iranian population. METHODS: This study follows a case- control study design, in which, 288 patients with chronic hepatitis C and 250 healthy individuals were genotyped for IL28B polymorphisms (rs12979860 C/T and rs8099917 G/T)...
December 2016: Gastroenterology and Hepatology From Bed to Bench
https://www.readbyqxmd.com/read/28214980/sil2r-ratio-as-early-marker-for-response-in-hairy-cell-leukemia-and-the-prognostic-relevance-of-il28b-genotype-to-interferon-%C3%AE-therapy
#2
Stéphanie Jud, Jeroen S Goede, Oliver Senn, Katharina Spanaus, Markus G Manz, Rudolf Benz
Interferon-α (IFNα) was the first effective drug therapy for hairy cell leukemia (HCL). Nowadays, it is used as an alternative treatment in selected patients. Due to unlimited treatment time, monitoring and early prediction of response are important. Moreover, IFNα is used in the therapy of chronic hepatitis C, where a single nucleotide polymorphism of interleukin-28B gene (IL28B) correlates with therapy response. The role of this polymorphism in therapy response of IFNα-treated patients with HCL is unknown...
February 18, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28144454/role-of-il28-b-polymorphism-rs12979860-on-sustained-virological-response-to-pegylated-interferon-ribavirin-in-iranian-patients-with-chronic-hepatitis-c
#3
Mahtab Daneshvar, Mehri Nikbin, Solmaz Talebi, Foozieh Javadi, Mohammad Reza Aghasadeghi, Sanaz Mahmazi, Seyed Mehdi Sadat
BACKGROUND: The current medical treatment for hepatitis C virus (HCV) infection is pegylated interferon plus ribavirin, but just 50% of genotype 1 HCV patients and about 80% of HCV genotype 3 patients are treated completely. Recently, the rs12979860 C/T polymorphism, which is located 3 kb upstream of the IL28b gene that codes IFNλ3, shows a powerful association in response to the treatment in HCV patients. OBJECTIVES: The aim of this study was to evaluate the relationship between IL28b single nucleotide polymorphism (SNP) and treatment outcomes among chronic HCV patients in Iran...
September 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28141591/impact-of-interleukin-28b-rs12979860-c-t-polymorphism-on-severity-of-disease-and-response-to-treatment-in-hepatitis-delta
#4
Murat Ispiroglu, Ibrahim Halil Bahcecioglu, Ulvi Demirel, Mehmet Yalniz
INTRODUCTION: Pegylated-interferon alpha (Peg-IFN α) is the therapy most commonly used to treat chronic hepatitis delta virus (HDV) infection. In the present study, we planned to investigate effect of IL28B polymorphism on response to Peg-IFN α therapy and disease progression in patients with chronic HDV. METHODOLOGY: A total of 47 patients who received Peg-IFNα therapy for at least one year were investigated. The patients were divided into three groups based on their response to treatment: sustained viral response (SVR) (32%), unresponsive (53%), and relapse (15%)...
January 30, 2017: Journal of Infection in Developing Countries
https://www.readbyqxmd.com/read/28072888/clinical-and-virological-predictors-of-sustained-response-with-an-interferon-based-simeprevir-regimen-for-patients-with-chronic-genotype-1-hepatitis-c-virus-infection
#5
Gianpiero D'Offizi, Calogero Cammà, Chiara Taibi, Michael Schlag, Karin Weber, Maria Palma, Ralph DeMasi, Katrien Janssen, James Witek, Raffaella Lionetti
Simeprevir plus peg-interferon/ribavirin (PR) is approved to treat chronic hepatitis C (HCV) genotype 1 (GT1) and GT4 infection. This study aimed to assess baseline and on-treatment the factors predictive of sustained virologic response 12-weeks post-treatment (SVR12) in patients receiving 12 weeks of simeprevir plus PR followed by 12 or 36 weeks of PR. Data from participants in four studies (QUEST-1, QUEST-2, ATTAIN and PROMISE) were pooled to examine the efficacy and safety of simeprevir+PR in HCV GT1 patients...
January 2017: New Microbiologica
https://www.readbyqxmd.com/read/28070198/clinical-course-and-genetic-susceptibility-of-primary-biliary-cirrhosis-analysis-of-a-prospective-cohort
#6
Piero Luigi Almasio, Anna Licata, Marcello Maida, Fabio Salvatore Macaluso, Andrea Costantino, Nicola Alessi, Stefania Grimaudo, Giulia Accardi, Calogero Caruso, Antonio Craxi
BACKGROUND: Natural history of primary biliary cirrhosis (PBC) is partially characterized in patients from the Mediterranean area whose genetic background differs from that of Northern Europeans. OBJECTIVES: We aimed to describe genetic susceptibility and clinical course of PBC in patients from Southern Italy. METHODS: Socio-demographic, clinical, biochemical and histological data at diagnosis as well as disease progression of 81 PBC consecutive patients were collected...
November 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/28056030/efficacy-of-a-12-week-simeprevir-plus-peginterferon-ribavirin-pr-regimen-in-treatment-na%C3%A3-ve-patients-with-hepatitis-c-virus-hcv-genotype-4-gt4-infection-and-mild-to-moderate-fibrosis-displaying-early-on-treatment-virologic-response
#7
Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti
BACKGROUND: HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12...
2017: PloS One
https://www.readbyqxmd.com/read/27943542/hbv-hcv-co-infection-is-associated-with-a-high-level-of-hcv-spontaneous-clearance-among-drug-users-and-blood-donors-in-china
#8
H Xiong, X Rong, M Wang, R Xu, K Huang, Q Liao, J Huang, J Chen, C Li, X Tang, Z Shan, M Zhang, K Nelson, Y Fu
Understanding the biology of spontaneous clearance of hepatitis C virus (HCV) infection could lead to improved strategies to prevent the sequelae associated with chronic HCV infection. Chronic infections with hepatitis virus are very common in China, but the factors associated with spontaneous clearance of HCV have not been adequately studied. We evaluated the spontaneous clearance of HCV among 1918 drug users and 1526 HCV-seropositive blood donors in Guangzhou, China. Among participants who were co-infected with hepatitis B virus (HBV), 41...
December 12, 2016: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27932134/efficacy-and-safety-of-therapy-with-simeprevir-and-sofosbuvir-in-liver-transplant-recipients-infected-by-hepatitis-c-virus-genotype-4-cohort-spanish-society-of-liver-transplantation-cohort
#9
G Sanchez Antolin, M Testillano, J M Pascasio, I Narvaez Rodriguez, M Prieto, A Otero, J I Herrero, M Londoño, I Fernandez Vazquez, L Castells
BACKGROUND: Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of 2nd-generation direct-acting antivirals (DAAs), and more data are needed to help guide treatment decisions. We still have even fewer data concerning liver transplant patients. Simeprevir (SIM) and sofosbuvir (SOF) combination is useful to treat this genotype. The aim of this study was to know the efficacy and safety of the combination SIM + SOF ± ribavirin (RBV) in a group of liver transplant patients with HCV genotype 4 infection in Spain in real life...
November 2016: Transplantation Proceedings
https://www.readbyqxmd.com/read/27917597/chronic-hepatitis-c-infection-and-liver-disease-in-hiv-coinfected-patients-in-asia
#10
N Durier, E Yunihastuti, K Ruxrungtham, N V Kinh, A Kamarulzaman, D Boettiger, A Widhani, A Avihingsanon, B V Huy, S F B Syed Omar, A Sanityoso, S Chittmittrapap, N T H Dung, V Pillai, T Suwan-Ampai, M Law, A H Sohn, G Matthews
Data on markers of hepatitis C virus (HCV) disease in HIV-HCV-coinfected patients in resource-limited settings are scarce. We assessed HCV RNA, HCV genotype (GT), IL28B GT and liver fibrosis (FibroScan(®) ) in 480 HIV-infected patients with positive HCV antibody in four HIV treatment centres in South-East Asia. We enrolled 165 (34.4%) patients in Jakarta, 158 (32.9%) in Bangkok, 110 (22.9%) in Hanoi and 47 (9.8%) in Kuala Lumpur. Overall, 426 (88.8%) were male, the median (IQR) age was 38.1 (34.7-42.5) years, 365 (76...
March 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/27917361/il28b-genotype-is-associated-with-cirrhosis-or-transition-to-cirrhosis-in-treatment-naive-patients-with-chronic-hcv-genotype-1-infection-the-international-observational-gen-c-study
#11
Alessandra Mangia, Victor De Ledinghen, François Bailly, Javier Brahm, Jazeps Keiss, Jonas Valantinas, Nele Rasmann, Diethelm Messinger, Fernando Tatsch, Georgios Bakalos, Graham R Foster
BACKGROUND AND PURPOSE: Contradictory data exist on the association between host interleukin-28B (IL28B) rs12979860 genotype and liver fibrosis in patients with chronic hepatitis C (CHC). This large, international, observational study (NCT01675427/MV25600) investigated relationships between IL28B rs12979860 genotype and liver fibrosis stage in CHC patients. METHODS: A total of 3003 adult, treatment-naive CHC patients were enrolled into the study. Patients made one study visit to provide a blood sample for genotyping; other data were obtained from medical records...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27895405/impact-of-il28b-and-oas-gene-family-polymorphisms-on-interferon-treatment-response-in-caucasian-children-chronically-infected-with-hepatitis-b-virus
#12
Krzysztof Domagalski, Małgorzata Pawłowska, Agnieszka Zaleśna, Małgorzata Pilarczyk, Paweł Rajewski, Waldemar Halota, Andrzej Tretyn
AIM: To investigate the impact of IL28B and OAS gene polymorphisms on interferon treatment responses in children with chronic hepatitis B. METHODS: We enrolled 52 children (between the ages of 4 and 18) with hepatitis B e antigen-negative chronic hepatitis B (CHB), who were treated with pegylated interferon alfa for 48 wk. Single nucleotide polymorphisms in the OAS1 (rs1131476), OAS2 (rs1293747), OAS3 (rs2072136), OASL (rs10849829) and IL28B (rs12979860, rs12980275 and rs8099917) genes were studied to examine their associations with responses to IFN treatment in paediatric patients...
November 7, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27877087/il28b-snp-rs12979860-is-the-critical-predictor-for-sustained-viral-response-in-chinese-children-aged-1-to-6-years-with-chronic-hepatitis-c
#13
Yan-Wei Zhong, Hong-Fei Zhang, Yan-Min Shi, Yong-Li Li, Fang Chu, Zhi-Qiang Xu, Da-Wei Chen, Yu Gan, Fu-Chuan Wang, Mei-Lei Gu, Yi Dong, Shi-Shu Zhu, Ce Shi, Hua-Hao Fan, Xiu-Chang Zhang, Min Zhang
Clinical data on children with chronic hepatitis C (CHC) remain extremely limited. This study investigated sustained virologic response (SVR) to alfa-interferon 2b plus RBV treatment in children aged 1-6 years with unsafe injection-acquired CHC. 154 children with CHC aged 1 to 6 years were enrolled, 101 of them were male (65.6%) and 53 were female (34.4%), and they were treated with alfa-interferon at a dose of 1-5 MIU/m(2) 3 times weekly plus oral RBV (15 mg/kg/day) for 48 weeks. 57(39.3 %) of them were genotype 1b, 73(50...
2016: International Journal of Biological Sciences
https://www.readbyqxmd.com/read/27875564/donor-ifnl4-genotype-is-associated-with-early-post-transplant-fibrosis-in-recipients-with-hepatitis-c
#14
Taylor Aiken, Ari Garber, Dawn Thomas, Nicole Hamon, Rocio Lopez, Rajesh Konjeti, Arthur McCullough, Nizar Zein, John Fung, Medhat Askar, Binu V John
BACKGROUND AND AIMS: Early post-transplant hepatic fibrosis is associated with poor outcomes and may be influenced by donor/recipient genetic factors. The rs368234815 IFNL4 polymorphism is related to the previously described IL28B polymorphism, which predicts etiology-independent hepatic fibrosis. The aim of this study was to identify the impact of donor and/or recipient IFNL4 genotype on early fibrosis among patients transplanted for hepatitis C (HCV). METHODS: Clinical data were collected for 302 consecutive patients transplanted for HCV...
2016: PloS One
https://www.readbyqxmd.com/read/27812403/the-impact-of-il-6-and-il-28b-gene-polymorphisms-on-treatment-outcome-of-chronic-hepatitis-c-infection-among-intravenous-drug-users-in-croatia
#15
Zoran Bogdanović, Ivana Marinović-Terzić, Sendi Kuret, Ana Jerončić, Nikola Bradarić, Gea Forempoher, Ozren Polašek, Šimun Anđelinović, Janoš Terzić
BACKGROUND: Several genes and their single nucleotide polymorphisms (SNPs) are associated with either spontaneous resolution of hepatitis C infection or better treatment-induced viral clearance. We tested a cohort of intravenous drug users (IVDU) diagnosed with chronic hepatitis C virus (HCV) for treatment response and its association with the SNPs in the interleukin-6 (rs1800795-IL6) and the interleukin-28B (rs12979860-IL28B) genes. METHODS: The study included 110 Croatian IVDU positive for anti-HCV antibody...
2016: PeerJ
https://www.readbyqxmd.com/read/27810523/correlation-of-interferon-lambda-4-ss469415590-with-the-hepatitis-c-virus-treatment-response-and-its-comparison-with-interleukin-28b-polymorphisms-in-predicting-a-sustained-virological-response-a-meta-analysis
#16
Yunhua Li, Luhua Yang, Kaihui Sha, Tonggang Liu, Liguo Zhang
BACKGROUND: Interferon-lambda 4 (IFNL4) ss469415590 is a newly discovered polymorphism that could predict the treatment response in hepatitis C virus (HCV)-infected patients. This meta-analysis was performed in order to clarify its specific effect on the treatment response and to compare it with interleukin 28b (IL28B). METHOD: The commonly used literature databases were searched. Meta-analyses were performed with fixed/random-effects models using Stata 12.0. The sustained virological response (SVR) rate was summarized using R software...
December 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/27753578/implementation-of-pharmacogenetic-testing-within-the-veterans-health-administration-from-2011-to-2013
#17
Julie Lynch, Scott L DuVall, Brygida Berse, Angela Whatley, Cathy St Pierre, Omobonike Oloruntoba, Christine M Hunt
We assessed implementation of precision medicine within the Veterans Health Administration. We analyzed the use of interleukin-28B (IL28B) pharmacogenetic test, which predicts interferon-α treatment response in patients with hepatitis C. Patients with favorable CC genotype exhibit a two-fold higher response than patients with less favorable genotypes (CT and TT). Linking IL28B tests to Veterans Health Administration clinical data, we analyzed test use, concordance with guidelines, subsequent interferon-α treatment, and site variations...
October 2016: Military Medicine
https://www.readbyqxmd.com/read/27751759/prevalence-and-clinical-implications-of-il28b-genotypes-in-taiwanese-patients-with-chronic-hepatitis-c
#18
Yone-Han Mah, Chen-Hua Liu, Chi-Ling Chen, Tai-Chung Tseng, Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao
BACKGROUND/PURPOSE: Clinical implications of IL28B gene in Taiwanese chronic hepatitis C (CHC) patients remain unknown. We thus investigated the prevalence and clinical implications of IL28B rs8099917 genotypes in CHC patients with different hepatitis C virus (HCV) genotypes and healthy controls. METHODS: A total of 200 HCV genotype 1 patients and 200 HCV genotype 2 patients who received liver biopsy, as well as 197 healthy controls were enrolled to determine the frequencies of IL28B rs8099917 genotypes...
November 2016: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/27740516/daclatasvir-and-peginterferon-ribavirin-for-black-african-american-and-latino-patients-with-hcv-infection
#19
Maribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, Lennox Jeffers, Steven-Huy Han, Paul J Thuluvath, Vinod Rustgi, Stephen Harrison, Reem Ghalib, John M Vierling, Velimir Luketic, Philippe J Zamor, Natarajan Ravendhran, Timothy R Morgan, Brian Pearlman, Christopher O'Brien, Hicham Khallafi, Nikolaos Pyrsopoulos, George Kong, Fiona McPhee, Philip D Yin, Eric Hughes, Michelle Treitel
:  Background. Patient race and ethnicity have historically impacted HCV treatment response. This phase 3 study evaluated daclatasvir with peginterferon-alfa-2a/ribavirin (pegIFN alfa-2a/RBV) in treatment-naive black/African American (AA), Latino, and white non-Latino patients with chronic HCV genotype 1 infection. MATERIAL AND METHODS: In this single-arm, open-label study, 246 patients received daclatasvir plus pegIFN alfa-2a and weight-based RBV. Patients with an extended rapid virologic response (eRVR; undetectable HCV-RNA at treatment weeks 4 and 12) received 24 weeks of treatment; those without eRVR received an additional 24 weeks of treatment with pegIFN alfa-2a/RBV...
November 2016: Annals of Hepatology
https://www.readbyqxmd.com/read/27729747/impact-of-hepatitis-c-virus-core-mutations-on-the-response-to-interferon-based-treatment-in-chronic-hepatitis-c
#20
Camelia Sultana, Gabriela Oprişan, Monica Delia Teleman, Sorin Dinu, Cristiana Oprea, Mihai Voiculescu, Simona Ruta
AIM: To determine whether hepatitis C virus (HCV) core substitutions play a role in the response to interferon-based treatment in Caucasian patients. METHODS: One hundred eight HCV chronically infected patients initiating treatment with pegylated IFN plus ribavirin for 48 wk were tested for baseline substitutions at codons 70 and 91 of the viral core protein (BigDye Terminator vers.3.1, Applied Biosystems,) and for genetic polymorphisms in host IL28B gene rs12979860 (Custom TaqMan 5' allelic discrimination assay; Applied Biosystems)...
October 7, 2016: World Journal of Gastroenterology: WJG
keyword
keyword
105030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"